Literature DB >> 12391282

Squalestatin 1-inducible expression of rat CYP2B: evidence that an endogenous isoprenoid is an activator of the constitutive androstane receptor.

Thomas A Kocarek1, Nancy A Mercer-Haines.   

Abstract

Because our previous studies indicated that squalestatin 1 treatment induces CYP2B expression in primary cultures of rat hepatocytes as a direct consequence of squalene synthase inhibition, we investigated possible underlying mechanisms. Cotransfection of cultured Sprague-Dawley male rat hepatocytes with each of the three sterol regulatory element binding protein (SREBP) transcription factors failed to induce luciferase expression from a squalestatin 1-responsive CYP2B1 reporter plasmid. Squalestatin 1 treatment of primary hepatocyte cultures from male Wistar-Kyoto rats produced a greater induction of CYP2B mRNA than occurred in cultures from female rats, consistent with the previously demonstrated response dimorphism that has been attributed to differences in constitutive androstane receptor (CAR) levels. Cotransfection of female Wistar-Kyoto rat hepatocyte cultures with plasmid expressing either mouse or rat CAR restored squalestatin 1-inducible CYP2B1-reporter expression. Cotransfection of Sprague-Dawley rat hepatocyte cultures with plasmid expressing rat CAR lacking the C-terminal AF-2 subdomain inhibited squalestatin 1-inducible CYP2B1-reporter expression. Squalestatin 1-mediated CYP2B mRNA induction in rat hepatocyte cultures was completely abolished by pretreatment with the 3-hydroxymethyl-3-glutaryl CoA reductase inhibitor pravastatin and was rescued by mevalonate supplementation, whereas phenobarbital-mediated induction was unaffected by these treatments. Finally, direct addition of trans,trans-farnesol to the culture medium caused the rapid induction of CYP2B mRNA. These results indicate that squalestatin 1 treatment induces CYP2B expression, not by inhibiting sterol synthesis and activating SREBPs, but by evoking the accumulation of an endogenous isoprenoid and activating CAR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12391282     DOI: 10.1124/mol.62.5.1177

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

1.  Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol.

Authors:  Satoshi Endo; Toshiyuki Matsunaga; Chisato Ohta; Midori Soda; Ayano Kanamori; Yukio Kitade; Satoshi Ohno; Kazuo Tajima; Ossama El-Kabbani; Akira Hara
Journal:  Chem Biol Interact       Date:  2010-12-25       Impact factor: 5.192

Review 2.  Small-molecule modulators of the constitutive androstane receptor.

Authors:  Milu T Cherian; Sergio C Chai; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-05-15       Impact factor: 4.481

3.  CAR2 displays unique ligand binding and RXRalpha heterodimerization characteristics.

Authors:  Scott S Auerbach; Joshua G Dekeyser; Matthew A Stoner; Curtis J Omiecinski
Journal:  Drug Metab Dispos       Date:  2006-12-28       Impact factor: 3.922

4.  Retinoid X receptor-alpha-dependent transactivation by a naturally occurring structural variant of human constitutive androstane receptor (NR1I3).

Authors:  Scott S Auerbach; Matthew A Stoner; Shengzhong Su; Curtis J Omiecinski
Journal:  Mol Pharmacol       Date:  2005-08-11       Impact factor: 4.436

5.  Upregulation of UGT2B4 Expression by 3'-Phosphoadenosine-5'-Phosphosulfate Synthase Knockdown: Implications for Coordinated Control of Bile Acid Conjugation.

Authors:  Kathleen G Barrett; Hailin Fang; Daniela Cukovic; Alan A Dombkowski; Thomas A Kocarek; Melissa Runge-Morris
Journal:  Drug Metab Dispos       Date:  2015-05-06       Impact factor: 3.922

6.  The role of cytochrome P450-dependent metabolism in the regulation of mouse hepatic growth hormone signaling components and target genes by 3-methylcholanthrene.

Authors:  Chunja Lee; Xinxin Ding; David S Riddick
Journal:  Drug Metab Dispos       Date:  2012-11-20       Impact factor: 3.922

7.  Transcriptional Regulation of Cytosolic Sulfotransferase 1C2 by Intermediates of the Cholesterol Biosynthetic Pathway in Primary Cultured Rat Hepatocytes.

Authors:  Elizabeth A Rondini; Asmita Pant; Thomas A Kocarek
Journal:  J Pharmacol Exp Ther       Date:  2015-10-01       Impact factor: 4.030

8.  Transcriptional Regulation of Human Cytosolic Sulfotransferase 1C3 by Peroxisome Proliferator-Activated Receptor γ in LS180 Human Colorectal Adenocarcinoma Cells.

Authors:  Sarah Dubaisi; Hailin Fang; Thomas A Kocarek; Melissa Runge-Morris
Journal:  Mol Pharmacol       Date:  2016-08-26       Impact factor: 4.436

9.  Farnesol is glucuronidated in human liver, kidney and intestine in vitro, and is a novel substrate for UGT2B7 and UGT1A1.

Authors:  Adam G Staines; Pavel Sindelar; Michael W H Coughtrie; Brian Burchell
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

10.  Regulation of murine hepatic hydroxysteroid sulfotransferase expression in hyposulfatemic mice and in a cell model of 3'-phosphoadenosine-5'-phosphosulfate deficiency.

Authors:  Kathleen G Barrett; Hailin Fang; Mary D Gargano; Daniel Markovich; Thomas A Kocarek; Melissa Runge-Morris
Journal:  Drug Metab Dispos       Date:  2013-05-14       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.